TARGET EU: The risk of angiooedema and other safety events in heart failure patients treated with sacubitril/valsartan compared to angiotensin-converting enzyme inhibitors First published 26/05/2026 Last updated 26/05/2026 EU PAS number:EUPAS1000001002 Study Ongoing